#1 Clinical Trials Search in Europe

Study of Fulvestrant and Abemaciclib for Women with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of breast cancer known as hormone receptor positive (HR+), HER2 negative breast cancer. This type of cancer is characterized by the presence of hormone receptors and the absence of a protein called HER2. The study involves women with this specific type of breast cancer that is either locally advanced, meaning it has spread to nearby tissues, or metastatic, meaning it has spread to other parts of the body.

The treatment being studied includes two medications: fulvestrant and abemaciclib. Fulvestrant is a type of endocrine therapy that works by blocking the effects of estrogen, a hormone that can promote the growth of breast cancer cells. Abemaciclib, also known by its code name LY2835219, is a targeted therapy that inhibits certain proteins called CDK4 and CDK6, which are involved in cell division and cancer growth. The study will compare the effects of using fulvestrant alone versus using fulvestrant combined with abemaciclib. Some participants will receive a placebo instead of abemaciclib to help determine the effectiveness of the combination treatment.

The purpose of the study is to evaluate how well the combination of fulvestrant and abemaciclib works in extending the time patients live without their cancer getting worse, known as progression-free survival. Participants will receive treatment over a period of time, and their health will be monitored regularly to assess the effects of the treatment. The study aims to provide valuable information on whether the combination of these medications can offer better outcomes for women with this type of breast cancer.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including a diagnosis of hormone receptor positive, HER2 negative breast cancer.

Participants must have either locally advanced disease not suitable for surgery or metastatic disease.

2 initial assessment

An initial assessment is conducted to evaluate the current health status and confirm postmenopausal status, either through natural or surgical menopause or ovarian suppression.

A negative serum pregnancy test is required within 14 days prior to randomization.

3 treatment phase

Participants receive fulvestrant as a solution for injection and abemaciclib for oral use.

Fulvestrant is administered as an injection, while abemaciclib is taken orally.

The treatment aims to compare the effectiveness of fulvestrant with abemaciclib versus fulvestrant with a placebo.

4 monitoring and follow-up

Regular monitoring is conducted to assess the progression-free survival (PFS), which is the primary endpoint of the study.

Participants are observed for any side effects or changes in health status throughout the study duration.

5 completion of study

The study is estimated to conclude by December 30, 2024.

Upon completion, participants may undergo final assessments to evaluate the overall outcomes of the treatment.

Who Can Join the Study?

  • Must have a diagnosis of HR+, HER2- breast cancer. HR+ means hormone receptor-positive, and HER2- means human epidermal growth factor receptor 2-negative.
  • Must have locally advanced disease that cannot be treated with surgery or have metastatic disease, which means the cancer has spread to other parts of the body.
  • Must meet one of the following conditions regarding disease progression and previous treatments:
    • Relapsed with evidence of cancer progression while on hormone therapy before surgery or after surgery, without receiving further hormone therapy after progression.
    • Relapsed with evidence of cancer progression within one year after finishing hormone therapy after surgery, without receiving further hormone therapy after progression.
    • Relapsed with evidence of cancer progression more than one year after finishing hormone therapy after surgery and then relapsed again after receiving treatment with either an antiestrogen or an aromatase inhibitor as the first hormone therapy for metastatic disease. Must not have received more than one type of hormone therapy or any chemotherapy for metastatic disease.
    • Initially presented with metastatic disease and then relapsed with evidence of cancer progression after receiving treatment with either an antiestrogen or an aromatase inhibitor as the first hormone therapy for metastatic disease. Must not have received more than one type of hormone therapy or any chemotherapy for metastatic disease.
  • Must be postmenopausal, which means no longer having menstrual periods, due to surgery, natural menopause, or ovarian suppression (started at least 28 days before the first day of the study) with a medication like goserelin.
  • Must have a negative pregnancy test at the start of the study and agree to use medically approved methods to prevent pregnancy during the study and for 12 weeks after the last dose of the study drug if postmenopausal status is due to ovarian suppression.
  • Must have either measurable disease, which means the cancer can be measured, or nonmeasurable bone-only disease.
  • Must have a performance status of 0 or 1 on the ECOG scale, which is a way to measure how well a person can perform daily activities.
  • Must have stopped previous cancer treatments, including hormone therapies, chemotherapy, radiotherapy, and immunotherapy, for at least 21 days for treatments that affect blood cells or 14 days for those that do not, before starting the study drug. Must have recovered from any immediate side effects of previous treatments, except for hair loss or nerve damage.
  • Must be female.
  • Must be within the age range of 18 to 65 years or older.

Who Cannot Join the Study?

  • Patients who are not women cannot participate.
  • Patients who do not have HR+ (hormone receptor-positive) and HER2- (human epidermal growth factor receptor 2-negative) breast cancer cannot participate.
  • Patients who do not have locally advanced or metastatic breast cancer cannot participate. Locally advanced means the cancer has spread to nearby tissues or lymph nodes, and metastatic means it has spread to other parts of the body.
  • Patients who are not within the specified age range cannot participate. The age range is typically defined by the study.
  • Patients who are considered part of a vulnerable population may not be eligible. Vulnerable population refers to groups who may have limited ability to give informed consent or are at higher risk of harm.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Katholieke Universiteit te Leuven Leuven Belgium

Other Sites

Site Name City Country Status
Istituto Oncologico Veneto Padua Italy
Centre hospitalier universitaire de Liege Liege Belgium
Hospital Universitario 12 De Octubre Madrid Spain
University General Hospital Of Heraklion Heraklion Greece
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida Lleida Spain
Uomkbqecxmqtma Cxhgpdh Kdlaacwbd Gdansk Poland
Uujlybohng Op Aycjcpo Edegem Belgium

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
22.07.2014
Greece Greece
Not recruiting
22.07.2014
Italy Italy
Not recruiting
22.07.2014
Poland Poland
Not recruiting
22.07.2014
Spain Spain
Not recruiting
22.07.2014

Trial locations

Investigated drugs:

Fulvestrant is a medication used in the treatment of hormone receptor-positive breast cancer. It works by blocking the effects of estrogen in the body, which can help slow down or stop the growth of certain types of breast cancer cells that need estrogen to grow.

Abemaciclib is a type of medication known as a CDK4/6 inhibitor. It is used in combination with other treatments for breast cancer. Abemaciclib works by interfering with the growth and division of cancer cells, which can help slow the progression of the disease. In this trial, it is being studied in combination with fulvestrant to see if it improves outcomes for women with hormone receptor-positive, HER2-negative breast cancer.

Investigated diseases:

Breast Cancer – Breast cancer is a disease where cells in the breast grow uncontrollably. It can begin in different parts of the breast, most commonly in the ducts or lobules. The disease may spread to nearby lymph nodes or other parts of the body. It is classified by the presence or absence of hormone receptors and the HER2 protein, which can influence its growth. Locally advanced breast cancer refers to cancer that has spread beyond the breast to nearby tissues but not to distant organs. Metastatic breast cancer indicates that the cancer has spread to other parts of the body, such as bones, liver, or lungs.

Trial ID:
2023-506781-30-00
Protocol code:
I3Y-MC-JPBL
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study to evaluate the use of [68Ga]BED003 for imaging colorectal, gastric, pancreatic, breast, and ovarian cancers.

    Recruiting

    2 1 1
    Investigated diseases:
    Italy The Netherlands

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain